Theravance Biopharma enters its second-half wind-down period with a definitive cash deal that effectively ends its independence as a standalone public company. In late June, the board approved an agreement to be acquired by Zymeworks for $17.00 per share in cash, an equity value of roughly $929 million. Shareholders also receive a contingent value right entitling them to 80% of net proceeds from any future ampreloxetine monetization over ten years. The offer sits 22% above the stock's close on that date, the day the CYPRESS study in ampreloxetine failed its primary endpoint, and 10% above the volume-weighted average since the failure.
The quarter's operating numbers tell a cleaner story than the headline loss suggests. Viatris collaboration revenue rose 11% year-over-year to $20.7 million, driven by YUPELRI U.S. net sales of $70.7 million and supported by a 10% gain in customer demand and strong hospital-channel growth. Operating expenses excluding restructuring and transaction costs fell 35% year-over-year after the spring reorganization. The company generated $9.5 million of non-GAAP net income from operations, a swing of $13.7 million from the prior-year non-GAAP loss. Cash and marketable securities stood at $387.7 million with no debt.
The central debate now is whether the $17.00 price adequately compensates shareholders for the YUPELRI royalty stream, the near-term TRELEGY milestone payment from Royalty Pharma, the Irish tax attributes, and the residual optionality on ampreloxetine. The Q2 print, combined with the restructuring savings that are now running, makes a credible case that the board's "greatest value" judgment is reasonable, though it is not the only reading of the evidence. The special general meeting to ratify the merger is scheduled for September 18, and the transaction is expected to close in the second half of 2026 subject to shareholder approval and customary regulatory conditions.